Emerging Therapeutic Targets for Soft Tissue Sarcoma

被引：1
作者：
Smith, Jason L. [1 ,2 ,3 ]
Riedel, Richard F. [1 ,4 ]
机构：
[1] Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Div Hematol, Durham, NC 27710 USA
[3] Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC 27710 USA
[4] Duke Univ, Duke Sarcoma Program, Duke Canc Inst, Med Ctr, Durham, NC 27710 USA
来源：
CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 04期
关键词：
Soft tissue sarcoma; Novel therapies; Molecular targets; GEMCITABINE PLUS DOCETAXEL; ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; RANDOMIZED PHASE-II; EUROPEAN-ORGANIZATION; DOUBLE-BLIND; IMATINIB MESYLATE; STROMAL TUMOR; TRABECTEDIN; INHIBITOR;
D O I：
10.1007/s11912-011-0175-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Soft tissue sarcomas (STS) are malignancies of mesenchymal origin that represent approximately 1% of cancers in adults. Systematic research into the treatment of STS is challenging given its rarity and disease heterogeneity. Despite the ability to histologically subtype STS, only recently has our approach to therapy begun to differentiate along these lines. The purpose of this review is to highlight emerging therapeutic targets and therapies that hold the potential to add to the current state of systemic treatment for STS.
引用
收藏
页码：350 / 358
页数：9
相关论文
共 89 条
  • [1] Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours
    Aleixo, P. B.
    Hartmann, A. A.
    Menezes, I. C.
    Meurer, R. T.
    Oliveira, A. M.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (12) : 1127 - 1135
  • [2] [Anonymous], J CLIN PATHOL
  • [3] [Anonymous], 2009 ASCO ANN ORL FL
  • [4] [Anonymous], 2009 ASCO ANN M ORL
  • [5] [Anonymous], 2010 ASCO ANN M CHIC
  • [6] [Anonymous], ANN ONCOL 0117
  • [7] [Anonymous], 2008 ASCO ANN M CHIC
  • [8] [Anonymous], 2008 ASCO ANN M CHIC
  • [9] [Anonymous], 2009 ASCO ANN M ORL
  • [10] [Anonymous], 2010 ASCO ANN M CHIC
123456789